AbbVie is officially based in Illinois, but a growing share of its profits is booked far from the United States, reflecting an intentional strategy of profit shifting to lower-tax jurisdictions. One of its most economically significant subsidiaries is Allergan Pharmaceuticals International Limited (APIL), an Irish entity whose low profile belies its central role in the group’s global tax strategy.
Between 2014 and 2023, Allergan’s (APIL) revenue exploded from $140 million to $4.5 billion, a staggering 3,119% increase. Yet over the same period, it posted more than $12 billion in cumulative net losses. In 2023, Allergan (APIL) generated nearly $2 billion in EBITDA—and still booked a net loss of $948 million. This isn’t bad botox business. It’s clever accounting.
The trick lies in Allergan’s (APIL) $14.5 billion trove of intangible assets—up from just $325,000 in 2014, a 44,500-fold increase. From 2014 to 2020, intangible assets grew by an astonishing 4,454,401%, reflecting a massive transfer of IP into the Irish entity—likely via inter-company restructuring or M&A activity. The timing overlaps perfectly with the end of the Double-Irish.
These assets, primarily intellectual property (or the economic license to exclusively use the IP) shifted from tax haven jurisdictions, generating massive amortisation expenses that drain profits. Between 2020 and 2023, intangible assets fell by 43.2%, from $14.48 billion to $8.23 billion—likely the result of amortisation, and possibly internal divestitures. In 2023 alone, Allergan wrote off $2.3 billion in amortisation and impairments.
Then there’s the interest. Allergan paid $647 million in 2023 to other AbbVie entities on intercompany loans—another way to extract earnings from Ireland while slashing taxable income. These loans don’t come from banks; they come from sister companies, often routed through other low-tax jurisdictions within Abbvie’s Multi-Jurisdictional Corporate Group (MJG).
This is where the mechanism of profit shifting becomes clear: by concentrating intellectual property ownership (or the licenses to use the IP) in Ireland and financing it with intercompany debt, AbbVie ensures that Allergan books large revenue inflows but is left with equally large deductions. The setup is designed to ensure that Ireland books the revenue, absorbs the costs, and ends up with nothing left to tax (at least in this subsidiary!).
It’s a classic strategy: stack the Irish entity with intellectual property, assign it ownership of global product rights, then let royalties and sales pour in. On paper, Allergan (APIL), looks like a multinational juggernaut. But behind the scenes, profits are siphoned out as quickly as they arrive.
Despite its multibillion-dollar turnover, Allergan (APIL) operates with just 120 employees out of a registered office in Dublin. AbbVie, by contrast, employs more than 55,000 people globally. That discrepancy says everything about where the value is created—and where the accounting says it ends up.
AbbVie’s consolidated 10k filings show the broader effect. In the U.S., it reports consistent domestic losses. Abroad, it’s extremely profitable.
Between 2014 and 2024, AbbVie paid only 3.4 billion dollars in tax on more than 115 billion dollars in foreign earnings, a foreign effective tax rate of just 2.9 percent. Meanwhile, despite reporting cumulative losses in the United States, it still paid 5.8 billion dollars in domestic tax.
These payments often reflected deferred tax accounting and the release of previously reserved liabilities, rather than current year profitability.This geographic pattern isn’t coincidence. It’s a product of legal-accounting design.
Allergan (APIL) functions as a central node in AbbVie’s global shifting wealth-chain. It holds massive amounts of intangible assets, receives revenue from foreign sales, logs amortisation and intercompany interest as expenses, and neutralises its taxable income. The result is an Irish-registered company that can claim billion-dollar operations while appearing to operate at a loss.
Ireland gets the sales, deductions go to Delaware, and dividends flow to Wall Street. This isn’t tax evasion. It’s tax engineering—perfectly legal and highly effective. AbbVie didn’t buy Allergan just for Botox. It bought a tax platform.
Leave a Reply